Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

678 Features
How to | Enter the cyberspace recruitment market

22 Nov 05

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Linda Eden-Ellis

Executive Jobs

11 Nov 05

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
Mike Wood

Pharmaceutical Abbreviations

31 Oct 05

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
Spencer Marsh

Would you like a chance to win £25!

24 Oct 05

Complete our user survey and you could win a £25 Amazon voucher!
Mike Wood

Diabetes

13 Oct 05

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
CSF Medical

PharmiWeb Solutions and Microsoft host unique seminar...and plan next one!

29 Sep 05

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
Colin Williams

PharmaSALES WORLD 2005

23 Sep 05

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Hannah Reading

Osteoporosis

23 Sep 05

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion.
CSF Medical

Exco Group- Win Small Business of the Year 2005

20 Sep 05

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
Sarah Eadon

U.S. and EU NME/NAS Submissions Hit Five-Year High in 2004

06 Sep 05

The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.
http://www.barnettinternational.com

Epilepsy

05 Sep 05

Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epilepsy remains important in helping to reduce the psychological and social sequelae which follow on from uncontrolled seizures.
CSF Medical

Schizophrenia

22 Aug 05

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical

Advances in the development of Cav2.2 (N-type) calcium channel blockers as analgesics.

18 Aug 05

According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
LeadDiscovery

Pancratistatin: A tumor selective apoptosis stimulator

18 Aug 05

Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
LeadDiscovery

Simvastatin as a disease modifying immunoregulatory candidate treatment of Parkinson's disease

18 Aug 05

Parkinson's disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003. Despite the commercial success associated with this therapy area, currently available treatments focus on levodopa which replaces the loss of striatal dopamine, the hall mark of Parkinson's disease, rather than targeting disease progression. The efficacy of levodopa eventually declines in most patients and new therapies with disease modifying activity are urgently required. A gr
LeadDiscovery

The combined use of angiotensin receptor blockers and long-acting calcium channel blockers as an effective approach to hypertension

18 Aug 05

Hypertension continues to represent a highly prevalent clinical problem affecting 190 million people in the 7 major pharmaceutical markets. This therapeutic area is also a highly lucrative field for pharmaceutical companies with sales exceeding $30 billion in 2003. Despite the improved efficacy and tolerability of the angiotensin receptor blocker class led by valsartan, physicians remain frustrated by the lack of efficacy of antihypertensive agents and the current trend is towards the use of com
LeadDiscovery

Histone deacetylase 2 (HDAC2): Modulation of HDAC2 and its implication for chronic obstructive airway diseases (COPD) and cancer.

18 Aug 05

Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors. As this class advances with therapeutic candidates now entering phase II trials, companies are seeking to optimize therapeutic margins by targeting specific isoforms of histone deacetylase that are involved in tumor progression. In a recent NEJM study Prof. Peter Barnes and colleagues demonstrates that the inhibition of HDAC2 could introduce airway risks, possibly e
LeadDiscovery

Dual VEGF- and Erb-receptor inhibition as an improved strategy for treating cancer

18 Aug 05

The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology and the recent success of Avastin, a monoclonal antibody that binds to and neutralizes one such growth factor, VEGF has not only resulted in the introduction of an effective clinical tool for the treatment of cancer but it also helped spark a wave of optimism in the angiogenesis inhibitor arena. As a result companies are evaluating new approaches to target VEGF in
LeadDiscovery

Optimizing gene transfection strategies for the targeted treatment of rheumatoid arthritis

18 Aug 05

Rheumatoid arthritis affects an estimated 2.1 million Americans. The initial success of biologics that neutralize TNF alpha mean that these therapeutics dominate the US and European rheumatoid arthritis markets. Although the development of biologics has revolutionized treatment of rheumatoid arthritis therapies remain far from optimal. Since biologics are peptidic in nature they must be administered by injection. Moreover, multiple dosing is required and this can be disruptive to the patient.
LeadDiscovery

FGF-21 as a candidate for the treatment of diabetes

18 Aug 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. Despite the presence of well established treatments of diabetes significant unmet needs remain driving a large body of research and development activity. The highlighted JCI paper described work by Lilly researchers advancing FGF-21 or its mimics as a novel therapeutic candidates for the treatment of diabetes.
LeadDiscovery

Actin Inhibition: The identification of PTX-2 as a novel anti-mitotic agent that selectively induces apoptosis in p53 deficient cancer cells

18 Aug 05

Although cytotoxics agents represent a cornerstone of oncology, toxicity and drug resistance has driven the development of targeted anticancer therapies. The current study highlights a novel antimitotic agent, PTX-2. This molecule, like the Taxol and Taxotere, blocks the cell cycle in late mitosis channelling cells into an apoptotic program. In direct contrast to Taxol and Taxotere, PTX-2 targets cells with p53 mutations; the plant alkaloids on the other hand are relatively insensitive in such c
LeadDiscovery

Targeting beta-catenin by celecoxib (Celebrex) as an anti-cancer mechanism of action and as a lead for the identification of improved oncology agents

18 Aug 05

Despite the cardiovascular risks that have recently emerged following prolonged treatment with COX-2 inhibitors, this class of drug continues to receive interest as an approach to chemoprevention. Celebrex, which was approved in 1998 for the treatment of familial adenomatous polyposis (FAP) has been shown to reduce the development of precancerous colorectal polyps by 28%. Data recently highlighted in the FASEB journal suggests that at least part of the efficacy of celebrex may be related to the
LeadDiscovery

Selection and Assessment Day

15 Aug 05

Clinical Research Academy has decided to implement a sure-fire way of finding top candidates for Clinical Research Associate (CRA) posts – by running a Selection and Assessment Day. The first was held at the end of July in Marlow in the UK.
Kieran.Engels

Milestone in the development of Histone Deacetylase Inhibitors

05 Aug 05

This alert is brought to you by LeadDiscovery and concerns today's announcement by Celera Genomics that clinical evaluation of their HDAC inhibitor CRA-024781 is about to commence. The press release is featured on today's edition of DailyUpdates-Oncology.
LeadDiscovery

PharmaReports Alert: Pain Therapeutics 2005

03 Aug 05

This PharmaReports alert (29th June, 2005) from LeadDiscovery announces the most recent report of pain to join the company's porfolio of pain reports. This report, Pain Therapeutics, 2005, provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.
LeadDiscovery

A-425619: A TRPV1 receptor antagonist with potential for the treatment of inflammatory, postoperative and arthritic pain

02 Aug 05

The worldwide analgesic market was worth $38 billion during the year 2002 and is expected to nearly double to $75 billion by the year 2010. The vanilloid receptor TRPV1 (VR1) has become an attractive molecular target for multiple sub-types of pain. Abbott researchers have recently described the development of A-425619
LeadDiscovery

Development stage candidate from Bayer Healthcare for the treatment of traumatic head injury, stroke, Parkinson's disease and Alzheimer' s disease

01 Aug 05

Acute neurodegeneration caused by stroke or trauma as well as more chronic disease resulting from Alzheimers’s disease or Parkinson’s disease has inflammatory and direct neurotoxic components. Bayer Healthcare researchers have developed a compound with anti-inflammatory and neuroprotective active resulting is therapeutic activity in models of head injury and Parkinson’s disease
LeadDiscovery

Taishi's 20-HETE synthesis inhibitor, TS-011 as a candidate acute treatment for hemorrhagic and ishemic stroke

28 Jul 05

Each year, 750,000 strokes occur in the US and resultant deaths account for stroke being one of the top three causes of mortality as well as a major economic burden on healthcare systems. One candidate molecular target for stroke is 20-HETE. Taisho Pharmaceutical have developed a potent and selective 20-HETE synthesis inhibitor, TS-011 for the treatment of stroke.
LeadDiscovery

Working in France

28 Jul 05

Tourists love France and why not you… to work and live in France.
Claire Armstrong i3 Pharma Resourcing

Vanilloid receptor desensitization as a strategy for improving glucose tolerance as well as reducing diabetic neuropathic pain

27 Jul 05

The vanilloid capsaicin has long been known to desensitize pain pathways leading to long-term analgesia. Recent data from Novo Nordisk A/S suggests that sensory afferents might also be implicated in the development of glucose intolerance.
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.